Bruce Power has received approval the Canadian Nuclear Safety Commission that will see new commercial production of medical isotopes.
The project would see the production of Lutetium 177, a medical isotope used to prostate cancer and neuroendocrine tumors.
The project is a partnership between Bruce Power, IsoGen, Saugeen Ojibway Nation (SON) and ITM.
Chief Development Officer and EVP Operational Services James Scongack says is another important step forward to utilize Bruce Power’s CANDU reactors to provide a new large-scale capacity for production in the medical isotope supply chain.
